Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ATAI Life Sciences N.V. - Common Shares (NQ:ATAI)

2.710 +0.520 (+23.74%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ATAI Life Sciences N.V. - Common Shares

< Previous 1 2
...
22 23 24 25 26 27 28 29 Next >
Atai Life Launches Depression-Focused Firm
Atai Life Sciences NV (NASDAQ: ATAI) has launched PsyProtix, a new platform company formed with Chymia LLC, a Duke University biotechnology spinout. ... 
Via Benzinga
Biotech Company Pasithea Therapeutics Teams Up With Evotec to Aid Mental Health Drug Discovery
Photo by CDC on Unsplash Pasithea Therapeutics (NASDAQ: KTTA), a Florida-based biotechnology company, has teamed with life sciences company Evotec SE (OTCMKTS: EVTCY) as its... 
Via Benzinga
Strong Pipeline of Drugs for Treatment Of Psychotic Disorders Anticipated To Drive The Market Through 2028
Palm Beach, FL –October 11, 2021 – FinancialNewsMedia.com News Commentary – There is a high demand for more advanced products for the treatment and maintenance of severe mental disorders. Thus,... 
Via FinancialNewsMedia
Where ATAI Life Sciences Stands With Analysts
ATAI Life Sciences (NASDAQ:ATAI) has observed the followi... 
Via Benzinga
What 9 Analyst Ratings Have To Say About ATAI Life Sciences
ATAI Life Sciences (NASDAQ:ATAI) has observed the following analyst rating... 
Via Benzinga
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16) Bio-Rad Laboratories, Inc... 
Via Benzinga
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (... 
Via Benzinga
The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 4) Avadel Pharmaceuticals plc (... 
Via Benzinga
NetworkNewsAudio – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Bringing Therapeutic Options to Diseases with Unmet Needs
Via Investor Brand Network
Topics Cannabis
Psychedelics Renaissance Underway as Paradigm Shifting Cure for Depression Potentially Discovered
Via FinancialNewsMedia
Topics Law Enforcement
Psyched: Delic Buys 10 Ketamine Clinics For $10M, Atai Launches Ibogaine Human Trials, Small Pharma Concludes Phase 1 DMT Study
The Week In Psychedelics: 
Via Benzinga
Investors Turning to Psychedelic Market as Renaissance Continues into New Wave of Diseases
Via Investor Brand Network
Topics Cannabis
Can Ibogaine Treat Opioid Addiction? Nasdaq-Listed Atai Is Launching A Trial To Find Out
DemeRx IB, Inc., a company developing psychedelic ibogaine for the treatment of opioid use disorder, has begun a phase 1/2... 
Via Benzinga
Psyched: First Active Psychedelics ETF Hits NYSE, Compass Dives Into Novel Molecules, Atai Subsidiary Launches Phase 2a Trial
AdvisorShares Launches First NYSE-listed Actively-managed Psychedelics ETF On Thursday, AdvisorShares 
Via Benzinga
$10 Billion Sackler Opioid Settlement Closes Chapter, Psychedelic Chapter Begins
Via FinancialNewsMedia
Can Ketamine For Depression Be Improved? New Study Will Looks Into Ketamine Analog Arketamine
Perception Neuroscience, an Atai Life Sciences (NASDAQ:ATAI) subsid... 
Via Benzinga
Psyched: CaamTech Raises $22M, Mydecine To Launch Smoking Cessation Trial, Michigan Bill Could Decriminalize Psychedelics
Last Week In Psychedelics: 
Via Benzinga
Psychedelic Medicine's Top CEOs: Who's Running The Biggest Companies In This Booming Industry?
By Natan Ponieman and Javier Hasse The psychedelic medicine industry is growing by leaps and bounds. Leading this charge is a group of ambitious and visionary corporate... 
Via Benzinga
Psychedelic Drug Industry Report Card For 2021
In assessing the psychedelic drug industry, a primary focus for investors is drug development. 
Via Talk Markets
What 10 Analyst Ratings Have To Say About ATAI Life Sciences
Analysts have provided the following ratings for ATAI Life Sciences (NASDAQ:AT... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 1, 2021
Upgrades For Chatham Lodging Trust (NYSE: 
Via Benzinga
21 Stocks Moving in Wednesday's Pre-Market Session
Gainers GBS Inc. (NASDAQ: GBS) rose 72.3% to $5.58 in pre-market trading. The company markets saliva test for diabetes management and previously announced collaboration on covid-... 
Via Benzinga
Psyched: Atai Launches 'Salvia Divinorum' Subsidiary, Mindset, Psilera and Wesana's Preclinical Trials, Origin Raises $5M
Atai Life Sciences Launches New Salvia Divinorum Subsidiary Atai Life Sciences (NASDAQ: 
Via Benzinga
Peter Thiel Backed Atai Life Launches New Mental Health Disorders-Focused Company
Peter Thiel-backed Atai Life Sciences (NASDAQ: ATAI) has launched a new portfolio company, Revixia Life Sciences. Revixia Life's primary mission is to... 
Via Benzinga
Atai Life Sciences To Research Potent Psychedelic Herb Salvia Divinorum Through Its New Subsidiary
Atai Life Sciences (NASDAQ:ATAI) has announced the launch ... 
Via Benzinga
Earnings Scheduled For August 16, 2021
Companies Reporting Before The Bell • Entera Bio (NASDAQ:ENTX) is likely to report earnings for its second quarter. • Data Storage (NASDAQ:DTST) is expected to... 
Via Benzinga
The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12) Adagio Therapeutics, Inc. (... 
Via Benzinga
The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Alnylam Pharmaceuticals,... 
Via Benzinga
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 9) Adagio Therapeutics, Inc. (... 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
Before 10 a.m. ET Monday, 63 stocks made new 52-week lows. Intriguing Points: The largest company by market cap to set a new 52-week low was PACCAR (NASDAQ:PCAR).... 
Via Benzinga
< Previous 1 2
...
22 23 24 25 26 27 28 29 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.